REGN
CALLS ▲Regeneron Pharmaceuticals, Inc.
$927.89
+13.33%delayed
News ▲ · Trend ▲ · above call trigger ▲
Expected move (1d)
▼ $900.79to$954.99 ▲
ATR ±$27.10 (+2.92%)Implied ±$45.80 (+4.94%)
Entry Reference
Price / prev close$927.89 / $818.77
Day range$839.08 – $935.34
52-wk range$591.52 – $935.35(98%)
Volume vs avg3.85×
ATR (14d)$27.10
MA 8 / 21$826.69 / $786.33
MA 50 / 200$793.30 / $737.54
Call ▲ / Put ▼ trigger$825.16 / $812.38
+1 / +2 ATR$954.99 / $982.08
-1 / -2 ATR$900.79 / $873.70
Support: 859.34 847.00 813.53
Resistance: -
Near-the-money contracts
exp 2026-11-06Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 840 | $89.75 | 68% | 0.88 | -1.41 | 4 |
| 850 | $79.90 | 62% | 0.87 | -1.36 | 34 |
| 890 | $43.90 | 49% | 0.75 | -1.55 | 1 |
| 910 | $29.15 | 45% | 0.64 | -1.67 | 17 |
| 920 | $22.80 | 45% | 0.57 | -1.73 | 19 |
| 950 | $8.70 | 44% | 0.36 | -1.59 | 4 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 770 | $0.05 | 85% | -0.04 | -0.76 | 6 |
| 780 | $0.05 | 81% | -0.05 | -0.75 | 2 |
| 790 | $18.00 | 76% | -0.05 | -0.74 | 1 |
| 800 | $21.82 | 71% | -0.05 | -0.72 | 2 |
| 810 | $1.00 | 66% | -0.06 | -0.71 | 2 |
| 817.5 | $23.00 | 70% | -0.08 | -0.99 | 7 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Regeneron Bolts 13% Higher, Breaking Out To A Two-Year High On Dupixent Dominance7h ago
- US Equity Markets End Lower After Sell-Off in Technology Stocks7h ago
- REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up10h ago
- Regeneron Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary11h ago
- What Just Happened To Alnylam Stock?11h ago
- Sanofi Q3 Earnings Call Highlights11h ago
- What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call11h ago
- Regeneron Bolts 11% Higher, Breaking Out To A Two-Year High On Dupixent Dominance12h ago
- Regeneron (REGN) Q3 2026 Earnings Call Transcript12h ago
- Regeneron Surges 13.55%: Here’s What It Means for Your Health Care ETFs12h ago
- Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever”13h ago
- Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript13h ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.